Abstract
Anthracyclines are among the most active cytotoxic drugs against breast cancer and are currently considered to be the standard agents for the adjuvant treatment of patients with node positive breast cancer. Nevertheless, the benefits attained by the use of the more active anthracycline schedules must be balanced against increased short- and long-term toxicity, and treatment options must be individualized for each patient. The authors review the available data regarding anthracycline efficacy and toxicity in the early breast cancer setting, the controversial issues still pending, and the potential directions for future research.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
